Dusty Swendson, DO
Internal Medicine · Salina, KSNPI 1952677601
Payments from drug & device makers
Across 105 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$413
- Lilly USA, LLC$328
- AbbVie$238
- AstraZeneca$192
- Novo Nordisk$140
- Pfizer$120
- plus $526 from 19 others
What the payments were for
- Food & beverage$1,957100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $413 |
| Lilly USA, LLC | 18 | $328 |
| AbbVie | 11 | $238 |
| AstraZeneca | 8 | $192 |
| Novo Nordisk | 8 | $140 |
| Pfizer | 8 | $120 |
| Amarin Pharma, Inc. | 3 | $75 |
| Novartis | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Insulet Corporation | 2 | $38 |
| Acadia Pharmaceuticals Inc | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Eisai Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Dexcom, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Bayer | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$137
How this compares
$1,957 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $171,767 |
| OzempicSemaglutide | 108 | $98,129 |
| JardianceEmpagliflozin | 111 | $96,119 |
| TrulicityDulaglutide | 86 | $87,533 |
| FarxigaDapagliflozin Propanediol | 133 | $73,007 |
| MounjaroTirzepatide | 51 | $52,176 |
| MyrbetriqMirabegron | 103 | $49,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $34,308 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $31,258 |
| XareltoRivaroxaban | 33 | $25,547 |
| RybelsusSemaglutide | 22 | $21,587 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $19,542 |
| JanuviaSitagliptin Phosphate | 39 | $18,928 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $18,245 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $18,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $120 | $171,767228 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $328 | $139,709137 claims |
| Novo NordiskOzempic, Rybelsus | $140 | $119,715130 claims |
| Boehringer IngelheimJardiance | $34 | $96,119111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $192 | $92,548156 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $15 | $67,31497 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $49,813103 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $12 | $31,40183 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $19 | $18,19519 claims |
| AbbVieLinzess | $238 | $11,44521 claims |
| NovartisEntresto | $45 | $11,31418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Salina
- Cameron Petro-SakurSalina$5K
- Martin KankamLeavenworth$63.4M
- Mark HamblinKansas City$5.2M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
- Leslie SpikesKansas City$4.5M
- Michael CoxTopeka$3.4M
- James RuhlmannHutchinson$2.8M
- Scott TeeterTopeka$1.2M
- Shadi HamdehKansas City$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.